Relenza (zanamivir) is an inhalation powder for oral inhalation approved for treatment of acute uncomplicated illness due to influenza A and B virus in adults and pediatric patients aged 7 years of age and older who have been symptomatic for no more than 2 days.
Relenza is indicated for preventive use (prophylaxis) in adults and pediatric patients aged 5 years of age and older.
Relenza is not a substitute for early influenza vaccination on an annual basis.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program using the contact information at the bottom of this page.
- Relenza: Consumer Questions and Answers
- Relenza (zanamivir) Inhalation Powder Dear Healthcare Professional Letter - October 2009
- Historical Information on Relenza (zanamivir)